Actively Recruiting
Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer
Led by Australasian Gastro-Intestinal Trials Group · Updated on 2026-05-08
30
Participants Needed
2
Research Sites
234 weeks
Total Duration
On this page
Sponsors
A
Australasian Gastro-Intestinal Trials Group
Lead Sponsor
T
Trans Tasman Radiation Oncology Group
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of this study is to investigate the effect of MRI-guided adaptive stereotactic radiotherapy on local control, survival, and toxicity in the treatment of oligometastatic cancer to the abdomen.
CONDITIONS
Official Title
Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older
- Diagnosis of oligometastatic disease from primary colorectal, upper gastrointestinal (gastric, oesophagus, pancreatic), breast, non-small cell lung, renal cell, or gynecological cancer
- Oligometastatic disease with controlled primary tumor and up to 5 metastatic lesions in a maximum of 2 organ systems including liver, adrenal, abdomino-pelvic lymph nodes, other abdominal or pelvic sites, and allowed bony or lung metastases only with abdominal site involvement
- De novo or metachronous oligometastatic disease with primary tumor treated with curative intent and no progression at primary site
- Histological confirmation of primary malignancy; biopsy of metastases if diagnosis uncertain
- All metastatic sites must be treatable with SABR
- Patients with oligo-progressive or oligo-persistent disease limited to a maximum of 2 progressive abdominal metastases in up to 2 organ systems
- Visible imaging targets suitable for SABR treatment
- Child-Pugh score A to B7 for liver treatment
- ECOG performance status 0 to 2
- Patient must provide consent
You will not qualify if you...
- Contraindication to MRI
- Previous high-dose radiotherapy to the treatment site, including SIRTEX
- Overlapping radiation volume with prior high-dose treatment
- Diagnosis of primary prostate cancer, carcinoid tumors, germ cell tumors, lymphoma, or small cell tumors
- Pregnant women
- Complete response of metastatic disease to systemic therapy with no target for SABR
- Medical conditions limiting prognosis more than cancer diagnosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
GenesisCare - St Vincent's Sydney
Darlinghurst, New South Wales, Australia, 2010
Actively Recruiting
2
Austin Health
Melbourne, Victoria, Australia, 3084
Not Yet Recruiting
Research Team
S
Sukanya Sathyamurthie
CONTACT
S
Sandra Bahamad
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here